Information Provided By: 
Fly News Breaks for March 4, 2020
VRTX
Mar 4, 2020 | 09:07 EDT
Barclays analyst Gena Wang initiated coverage of Vertex Pharmaceuticals with an Overweight rating and $271 price target. Vertex has "flawlessly" executed the drug development for cystic fibrosis to build a franchise that could address ~90% of patient population, Wang tells investors in a research note. The analyst believes the company looks well poised for short- and long-term growth from its "dominant" CF franchise.
News For VRTX From the Last 2 Days
There are no results for your query VRTX
